Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age

Background. Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated. Methods. African children...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Infect Dis
Main Authors: Tapia, Milagritos D., Findlow, Helen, Idoko, Olubukola T., Preziosi, Marie-Pierre, Kulkarni, Prasad S., Enwere, Godwin C., Elie, Cheryl, Parulekar, Varsha, Sow, Samba O., Haidara, Fadima Cheick, Diallo, Fatoumata, Doumbia, Moussa, Akinsola, Adebayo K., Adegbola, Richard A., Kampmann, Beate, Chaumont, Julie, Martellet, Lionel, Marchetti, Elisa, Viviani, Simonetta, Tang, Yuxiao, Plikaytis, Brian D., Marc LaForce, F., Carlone, George, Borrow, Ray
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639509/
https://ncbi.nlm.nih.gov/pubmed/26553683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ672
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados